Profile data is unavailable for this security.
About the company
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
- Revenue in USD (TTM)247.00m
- Net income in USD-180.81m
- Incorporated1999
- Employees597.00
- LocationRevance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
- Phone+1 (615) 724-7755
- Fax+1 (302) 655-5049
- Websitehttps://www.revance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lifecore Biomedical Inc | 128.45m | 5.71m | 257.05m | 524.00 | 188.96 | -- | 17.86 | 2.00 | 0.0369 | 0.0595 | 3.82 | 1.28 | 0.5217 | 2.01 | 4.96 | 245,124.00 | 2.32 | -5.91 | 2.74 | -8.33 | 34.65 | 31.01 | 4.45 | -19.16 | 0.803 | 0.125 | 0.7641 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
| Precigen Inc | 3.96m | -139.56m | 257.82m | 202.00 | -- | 4.78 | -- | 65.06 | -0.5479 | -0.5479 | 0.0154 | 0.1891 | 0.0289 | -- | 5.40 | 19,618.81 | -101.81 | -31.50 | -126.84 | -38.63 | -12.44 | 44.00 | -3,521.68 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Eton Pharmaceuticals Inc | 34.68m | -5.48m | 277.74m | 30.00 | -- | 17.38 | -- | 8.01 | -0.2135 | -0.2135 | 1.34 | 0.6186 | 1.03 | 9.44 | 7.63 | 1,155,900.00 | -16.27 | -46.22 | -29.44 | -58.20 | 59.30 | 72.16 | -15.81 | -76.86 | 1.41 | -- | 0.2052 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Sanara Medtech Inc | 78.06m | -8.36m | 326.44m | 107.00 | -- | 8.20 | -- | 4.18 | -0.9871 | -0.9871 | 9.24 | 4.55 | 0.9518 | 1.91 | 8.39 | 729,503.40 | -10.33 | -17.73 | -12.37 | -22.07 | 90.16 | 88.08 | -10.86 | -17.13 | 2.02 | -3.44 | 0.4326 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Amylyx Pharmaceuticals Inc | 196.49m | -259.47m | 355.76m | 384.00 | -- | 1.81 | -- | 1.81 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Revance Therapeutics Inc | 247.00m | -180.81m | 402.83m | 597.00 | -- | -- | -- | 1.63 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Aquestive Therapeutics Inc | 58.90m | -35.19m | 411.21m | 135.00 | -- | -- | -- | 6.98 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Rigel Pharmaceuticals Inc | 157.47m | 3.88m | 441.08m | 147.00 | 115.56 | -- | 76.07 | 2.80 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| SIGA Technologies Inc | 173.73m | 85.71m | 447.49m | 45.00 | 5.28 | 2.64 | 5.19 | 2.58 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Xeris Biopharma Holdings Inc | 187.36m | -63.11m | 452.96m | 377.00 | -- | -- | -- | 2.42 | -0.4388 | -0.4388 | 1.30 | -0.1901 | 0.5775 | 0.8389 | 4.30 | 496,978.80 | -19.45 | -43.60 | -26.81 | -56.57 | 81.36 | 78.23 | -33.69 | -143.08 | 1.29 | -1.86 | 1.14 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Theravance Biopharma Inc | 63.19m | -49.40m | 470.14m | 99.00 | -- | 2.55 | -- | 7.44 | -1.01 | -1.01 | 1.29 | 3.78 | 0.1642 | -- | 3.73 | 638,303.00 | -12.84 | -40.51 | -13.71 | -48.50 | -- | -- | -78.18 | -305.27 | -- | -- | 0.1379 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 295.45m | -86.77m | 486.68m | 240.00 | -- | -- | -- | 1.65 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Zevra Therapeutics Inc | 24.79m | -84.93m | 487.32m | 65.00 | -- | 6.97 | -- | 19.66 | -1.96 | -1.96 | 0.5825 | 1.31 | 0.150 | -- | 2.80 | 381,323.10 | -51.39 | -32.11 | -61.91 | -39.89 | 53.72 | -- | -342.63 | -128.42 | -- | -25.93 | 0.4578 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Emergent Biosolutions Inc | 1.13bn | -208.80m | 509.33m | 1.60k | -- | 1.00 | -- | 0.4525 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.20 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| SNDL Inc | 652.27m | -79.06m | 525.69m | 2.52k | -- | 0.6076 | -- | 0.8059 | -0.3017 | -0.3017 | 2.48 | 3.26 | 0.6062 | 4.98 | 36.38 | 259,248.20 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD
37.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 7.81m | 7.50% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.46m | 5.24% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 4.74m | 4.56% |
| Fidelity Investments Canada ULCas of 30 Sep 2024 | 4.19m | 4.03% |
| Alpine Associates Management, Inc.as of 30 Sep 2024 | 4.16m | 4.00% |
| AllianceBernstein LPas of 30 Sep 2024 | 3.26m | 3.13% |
| Magnetar Financial LLCas of 30 Sep 2024 | 2.50m | 2.40% |
| Tang Capital Management LLCas of 30 Sep 2024 | 2.50m | 2.40% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.43m | 2.34% |
| Water Island Capital LLCas of 30 Sep 2024 | 2.38m | 2.29% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
